|
STAR TRIAL BEGINS ACCRUAL This
is the second NCI-funded breast cancer prevention trial which opened in May 1999 at 400 Centers in the United States, Puerto Rico and Canada. The Study Of Tamoxifen And Raloxifene (STAR) will begin enrolling 22,000
post-menopausal women who are high risk for breast cancer. Tamoxifen (nolvadex TM), in the National Surgical Adjuvant Breast and Bowel Project (NSABP) P-1 trial demonstrated a 50% reduction in breast cancer
incidence among those women at high-risk for developing breast cancer ( ie women with a mother, sister or daughter who have had breast cancer or a previous biopsy demonstrating atypia or lobular carcinoma –in-situ or
those over age 60). Although no study was designed to look specifically at the reduction in breast cancer incidence using Raloxifene (Evista TM) - - the MORE study (Multiple Outcomes of Raloxifene Evaluation
study) found a 76% reduction in invasive breast cancer incidence in 7,705 postmenopausal women with osteoporosis randomized to placebo or Raloxifene with a median follow-up of 40 months. The risk of thromboembolic
events is increased in both users of tamoxifen and Raloxifene and an increase in endometrial cancer is observed in tamoxifen users.(Call 412 330-4660 for information on the STAR trial) |
|
